User login
Key clinical point: Atogepant was effective in reducing monthly migraine days (MMD), monthly headache days (MHD), and acute medication use days in patients with chronic migraine (CM), irrespective of acute medication overuse.
Major findings: Patients with acute medication overuse receiving 30 mg or 60 mg atogepant vs placebo had a significantly greater reduction in MMD (least squares mean difference [LSMD] −2.7 and −1.9, respectively), MHD (LSMD −2.8 and −2.1, respectively), and monthly acute medication use days (LSMD −2.8 and −2.6, respectively). Similar reductions were observed in patients without acute medication overuse.
Study details: This subgroup analysis of the PROGRESS trial included 755 patients with CM with or without acute medication overuse who were randomly assigned to receive atogepant (30 mg or 60 mg) or placebo.
Disclosures: This study was funded by AbbVie. Six authors declared being employees or stockholders of AbbVie. Several authors declared having ties with various sources, including AbbVie.
Source: Goadsby PJ, Friedman DI, Holle-Lee D, et al. Efficacy of atogepant in chronic migraine with and without acute medication overuse in the randomized, double-blind, phase 3 PROGRESS trial. Neurology. 2024;103(2):e209584 (July 23). Doi: 10.1212/WNL.0000000000209584 Source
Key clinical point: Atogepant was effective in reducing monthly migraine days (MMD), monthly headache days (MHD), and acute medication use days in patients with chronic migraine (CM), irrespective of acute medication overuse.
Major findings: Patients with acute medication overuse receiving 30 mg or 60 mg atogepant vs placebo had a significantly greater reduction in MMD (least squares mean difference [LSMD] −2.7 and −1.9, respectively), MHD (LSMD −2.8 and −2.1, respectively), and monthly acute medication use days (LSMD −2.8 and −2.6, respectively). Similar reductions were observed in patients without acute medication overuse.
Study details: This subgroup analysis of the PROGRESS trial included 755 patients with CM with or without acute medication overuse who were randomly assigned to receive atogepant (30 mg or 60 mg) or placebo.
Disclosures: This study was funded by AbbVie. Six authors declared being employees or stockholders of AbbVie. Several authors declared having ties with various sources, including AbbVie.
Source: Goadsby PJ, Friedman DI, Holle-Lee D, et al. Efficacy of atogepant in chronic migraine with and without acute medication overuse in the randomized, double-blind, phase 3 PROGRESS trial. Neurology. 2024;103(2):e209584 (July 23). Doi: 10.1212/WNL.0000000000209584 Source
Key clinical point: Atogepant was effective in reducing monthly migraine days (MMD), monthly headache days (MHD), and acute medication use days in patients with chronic migraine (CM), irrespective of acute medication overuse.
Major findings: Patients with acute medication overuse receiving 30 mg or 60 mg atogepant vs placebo had a significantly greater reduction in MMD (least squares mean difference [LSMD] −2.7 and −1.9, respectively), MHD (LSMD −2.8 and −2.1, respectively), and monthly acute medication use days (LSMD −2.8 and −2.6, respectively). Similar reductions were observed in patients without acute medication overuse.
Study details: This subgroup analysis of the PROGRESS trial included 755 patients with CM with or without acute medication overuse who were randomly assigned to receive atogepant (30 mg or 60 mg) or placebo.
Disclosures: This study was funded by AbbVie. Six authors declared being employees or stockholders of AbbVie. Several authors declared having ties with various sources, including AbbVie.
Source: Goadsby PJ, Friedman DI, Holle-Lee D, et al. Efficacy of atogepant in chronic migraine with and without acute medication overuse in the randomized, double-blind, phase 3 PROGRESS trial. Neurology. 2024;103(2):e209584 (July 23). Doi: 10.1212/WNL.0000000000209584 Source